Enovis Corporation $ENOV Shares Sold by Tributary Capital Management LLC

Tributary Capital Management LLC lessened its holdings in Enovis Corporation (NYSE:ENOV) by 8.6% during the 4th quarter, HoldingsChannel.com reports. The firm owned 527,707 shares of the company’s stock after selling 49,534 shares during the period. Tributary Capital Management LLC’s holdings in Enovis were worth $14,058,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Farther Finance Advisors LLC lifted its stake in shares of Enovis by 42.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock valued at $37,000 after purchasing an additional 367 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after purchasing an additional 707 shares during the last quarter. SJS Investment Consulting Inc. lifted its stake in shares of Enovis by 30,340.0% in the 3rd quarter. SJS Investment Consulting Inc. now owns 1,522 shares of the company’s stock valued at $46,000 after purchasing an additional 1,517 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Enovis by 353.5% in the 4th quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock valued at $49,000 after purchasing an additional 1,446 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its stake in shares of Enovis by 235.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,703 shares of the company’s stock valued at $52,000 after purchasing an additional 1,195 shares during the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Insider Transactions at Enovis

In related news, insider Oliver Engert purchased 1,000 shares of Enovis stock in a transaction on Friday, February 27th. The shares were bought at an average price of $25.50 per share, with a total value of $25,500.00. Following the transaction, the insider directly owned 43,640 shares of the company’s stock, valued at approximately $1,112,820. This trade represents a 2.35% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders bought 5,000 shares of company stock valued at $121,983. 2.70% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several brokerages have recently commented on ENOV. Needham & Company LLC upped their price target on Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. BTIG Research upped their price target on Enovis from $41.00 to $43.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Evercore reissued an “outperform” rating on shares of Enovis in a research note on Monday, January 12th. William Blair started coverage on Enovis in a research note on Friday. They set an “outperform” rating on the stock. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Enovis in a research note on Friday, April 10th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Enovis presently has an average rating of “Buy” and an average price target of $47.43.

Enovis Price Performance

ENOV stock opened at $26.32 on Friday. The company has a debt-to-equity ratio of 0.85, a current ratio of 2.02 and a quick ratio of 1.04. The firm has a market capitalization of $1.51 billion, a P/E ratio of -1.27 and a beta of 1.47. The business’s 50-day moving average is $23.39 and its two-hundred day moving average is $26.40. Enovis Corporation has a 1 year low of $21.00 and a 1 year high of $37.85.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.95 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.81 by $0.14. The company had revenue of $575.76 million for the quarter, compared to analyst estimates of $584.30 million. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.Enovis’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.98 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Analysts anticipate that Enovis Corporation will post 2.79 earnings per share for the current fiscal year.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.